Results 21 to 30 of about 97,876 (294)

Increased expression of 5-hydroxytryptamine(2A/B) receptors in idiopathic pulmonary fibrosis: a rationale for therapeutic intervention [PDF]

, 2010
Background Idiopathic pulmonary fibrosis (IPF) has a poor prognosis and limited responsiveness to available treatments. It is characterised by epithelial cell injury, fibroblast activation and proliferation and extracellular matrix deposition ...
Amarie, Oana Veronica, Dumitrascu, Rio, Eickelberg, Oliver, Grimminger, Friedrich, Königshoff, Melanie, Reiter, Rudolf, Schermuly, Ralph Theo, Seeger, Werner, Udalov, Sergey   +8 more
core   +1 more source

Bleomycin induced urethral stricture in Hodgkin′s disease

Indian Journal of Urology, 2009
Bleomycin is a glycoprotein that is extensively used in combination with other anti-cancer agents because of its relative lack of hematological and gastrointestinal toxicity. However, pulmonary toxicity is common with bleomycin and limits its therapeutic
Ritesh Tapkire, N Kathiresan, B Satheesan   +2 more
doaj   +1 more source

Partial omission of bleomycin for early‐stage Hodgkin lymphoma patients treated with combined modality therapy: Does incomplete ABVD lead to inferior outcomes?

eJHaem, 2020
Classical Hodgkin lymphoma (HL) patients achieve excellent outcomes; therefore, treatment de‐escalation strategies to spare toxicity have been prioritized.
Jillian R. Gunther, Chelsea C. Pinnix, Gordon R. Glober, Kaitlin M. Christopherson, Penny Fang, Hun Ju Lee, Sairah Ahmed, Raphael E. Steiner, Ranjit Nair, Paolo Strati, Sattva S. Neelapu, Loretta J. Nastoupil, Bouthaina S. Dabaja   +12 more
doaj   +1 more source

Ameliorative Potential of Donepezil with or without Prednisolone in Bleomycin-Induced Pulmonary Fibrosis in Rats: Involvement of the Anti-Inflammatory, Antioxidant, and the Antifibrotic Pathways

Medicina, 2023
Background and Objectives: Bleomycin-induced pulmonary fibrosis is one of the serious complications that may limit the use of bleomycin in cancer therapy. To date, there is no effective remedy for the amelioration of this condition.
Shery Mina, Dina M. Elfeky, Ahmed M. Kabel, Sabeha E. Hedya   +3 more
doaj   +1 more source

Genetic partitioning of interleukin-6 signalling in mice dissociates Stat3 from Smad3-mediated lung fibrosis [PDF]

, 2012
Idiopathic pulmonary fibrosis (IPF) is a fatal disease that is unresponsive to current therapies and characterized by excessive collagen deposition and subsequent fibrosis.
Anderson, G.P., Bozinovski, S., Ernst, M.R., Jarnicki, A.G., Jones, J., Knight, D.A., Lau, H.L., Laurent, G.J., McAnulty, R.J., McKenzie, B.S., Mutsaers, S.E., O'Donoghue, R.J.J., Prêle, C.M., Richards, C.D., Rose-John, S., Stumbles, P.A., Thiem, S., Vlahos, R., Wang, B., Zhu, H.J.   +19 more
core   +2 more sources

Enhancing the efficacy of cytotoxic agents for cancer therapy using photochemical internalisation. [PDF]

, 2015
Photochemical internalisation (PCI) is a technique for improving cellular delivery of certain bioactive agents which are prone to sequestration within endolysosomes.
Adigbli, Adigbli, Arentsen, Baglo, Berg, Berg, Berg, Berg, Berstad, Bodles-Brakhop, Bostad, Bostad, Bull-Hansen, Castano, Castano, Chong, Dietze, Dietze, Elisabeth Olsen, Fretz, Gaware, Gooding, Gottesman, Hirschberg, Høgset, Jørgensen, Kunz, Lai, Lai, Lakshmanan, Lou, Lu, Lund, Mathews, Mroz, Mroz, Norum, Norum, Norum, Norum, Pasparakis, Peng, Peng, Prasmickaite, Reginato, Rosenblum, Selbo, Selbo, Selbo, Selbo, Selbo, Selbo, Selbo, Selbo, Selbo, St Denis, Stratford, Todorova, Vikdal, Wang, Wang, Wang, Weyergang, Weyergang, Woodhams, Xu, Yaghini, Yao, Yip, Zahreddine   +69 more
core   +1 more source

Tackling MARCKS-PIP3 circuit attenuates fibroblast activation and fibrosis progression. [PDF]

, 2019
Targeting activated fibroblasts, including myofibroblast differentiation, has emerged as a key therapeutic strategy in patients with idiopathic pulmonary fibrosis (IPF).
Chen, Ching-Hsien, Last, Jerold A, Li, Ji-Min, Oldham, Justin, Phan, Sem H, Wu, Reen, Xu, Jihao, Yang, David C   +7 more
core   +2 more sources

Intralesional bleomycin for treatment of a recalcitrant wart in an immunocompromised patient: A safe, effective, and underutilized therapy

Clinical Case Reports, 2022
Injectable bleomycin is infrequently used for recalcitrant warts despite its efficacy, acceptable safety profile, and high patient satisfaction compared with other treatment modalities.
Tracy Ngo, Hannah Hwang, Bijal Amin, Steven R. Cohen   +3 more
doaj   +1 more source

Enhancement of bleomycin production in Streptomyces verticillus through global metabolic regulation of N-acetylglucosamine and assisted metabolic profiling analysis

Microbial Cell Factories, 2020
Background Bleomycin is a broad-spectrum glycopeptide antitumor antibiotic produced by Streptomyces verticillus. Clinically, the mixture of bleomycin A2 and bleomycin B2 is widely used in combination with other drugs for the treatment of various cancers.
Hong Chen, Jiaqi Cui, Pan Wang, Xin Wang, Jianping Wen   +4 more
doaj   +1 more source

Flagellate dermatitis in a patient with testicular germ cell neoplasia on bleomycin

Dermatology Reports, 2023
Bleomycin, an antineoplastic antibiotic that inhibits DNA synthesis, is used to treat various malignant tumours such as Hodgkin's lymphoma, squamous cell carcinoma, and germ cell tumors.
Konstantina Mavridou, Aggeliki Karakasi, Evangeli Lampri, George Gaitanis, Ioannis D Bassukas   +4 more
doaj   +1 more source